ZA201300957B - 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof - Google Patents

5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof

Info

Publication number
ZA201300957B
ZA201300957B ZA2013/00957A ZA201300957A ZA201300957B ZA 201300957 B ZA201300957 B ZA 201300957B ZA 2013/00957 A ZA2013/00957 A ZA 2013/00957A ZA 201300957 A ZA201300957 A ZA 201300957A ZA 201300957 B ZA201300957 B ZA 201300957B
Authority
ZA
South Africa
Prior art keywords
dihydroquinoline
carboxamide
oxo
chloro
hydroxy
Prior art date
Application number
ZA2013/00957A
Other languages
English (en)
Inventor
Ulf Tomas Fristedt
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA201300957B publication Critical patent/ZA201300957B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
ZA2013/00957A 2010-07-09 2013-02-05 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof ZA201300957B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39926410P 2010-07-09 2010-07-09
PCT/US2011/043391 WO2012006544A1 (en) 2010-07-09 2011-07-08 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Publications (1)

Publication Number Publication Date
ZA201300957B true ZA201300957B (en) 2014-04-30

Family

ID=45439027

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/00957A ZA201300957B (en) 2010-07-09 2013-02-05 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof

Country Status (14)

Country Link
US (3) US20120010239A1 (enExample)
EP (2) EP3056205A1 (enExample)
JP (2) JP5934202B2 (enExample)
KR (1) KR20130041193A (enExample)
CN (1) CN102985090B (enExample)
AU (2) AU2011274502A1 (enExample)
BR (1) BR112013000607A2 (enExample)
CA (1) CA2804989A1 (enExample)
EA (1) EA201390074A1 (enExample)
HK (1) HK1225308A1 (enExample)
MX (1) MX2013000332A (enExample)
NZ (1) NZ606589A (enExample)
WO (1) WO2012006544A1 (enExample)
ZA (1) ZA201300957B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107176923A (zh) * 2005-10-19 2017-09-19 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
KR101495327B1 (ko) 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
ES2731052T3 (es) 2009-08-10 2019-11-13 Active Biotech Ab Tratamiento de la enfermedad de Huntington usando laquinimod
KR20150135552A (ko) 2010-03-03 2015-12-02 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
WO2011109531A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
JP2013535437A (ja) 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
UY36099A (es) 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
US20190090046A1 (en) * 2017-09-21 2019-03-21 Bragi GmbH Tactile Feedback for Audio Defined Menu System and Method
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2380420A (en) * 1940-12-16 1945-07-31 William S Emerson Production of secondary and tertiary amines from nitrogen compounds
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3724018A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur trennung von anilin-derivaten
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
CN107176923A (zh) 2005-10-19 2017-09-19 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
KR101495327B1 (ko) * 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US8178127B2 (en) * 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
WO2010001257A2 (en) * 2008-07-01 2010-01-07 Actavis Group Ptc Ehf Novel solid state forms of laquinimod and its sodium salt
US20120009226A1 (en) * 2008-12-17 2012-01-12 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
CA2804989A1 (en) 2012-01-12
BR112013000607A2 (pt) 2016-06-28
EP3056205A1 (en) 2016-08-17
MX2013000332A (es) 2013-02-26
WO2012006544A1 (en) 2012-01-12
US20160279121A1 (en) 2016-09-29
JP2013534536A (ja) 2013-09-05
US20180140592A1 (en) 2018-05-24
US20120010239A1 (en) 2012-01-12
JP2016053049A (ja) 2016-04-14
CN102985090B (zh) 2014-11-26
KR20130041193A (ko) 2013-04-24
EA201390074A1 (ru) 2013-06-28
AU2017261621A1 (en) 2017-12-07
EP2590653A1 (en) 2013-05-15
CN102985090A (zh) 2013-03-20
AU2011274502A1 (en) 2013-02-28
EP2590653A4 (en) 2014-01-01
NZ606589A (en) 2015-03-27
HK1225308A1 (en) 2017-09-08
JP5934202B2 (ja) 2016-06-15

Similar Documents

Publication Publication Date Title
ZA201300957B (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof
IL251600A0 (en) En-ethyl-en-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide containing deuterium, and salts and uses of the substance
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
IL253870A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
SI2539326T1 (sl) Bisaril-vezani ariltriazoloni in njihova uporaba
ZA201208578B (en) Composition,method and use
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
ZA201208173B (en) Peptices and their use
GB201010193D0 (en) Medicinal use
ZA201207178B (en) Oxadiazole compounds,their preparation and use
ZA201303773B (en) Compounds and their use
SI2552440T1 (sl) Nove kombinacije in uporaba
PL2603217T3 (pl) Nowe pochodne 6,7-dipodstawionej izochinoliny i ich zastosowanie
EP2621490A4 (en) PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
HK1178082A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
GB201001670D0 (en) Use
GB201000631D0 (en) New use
GB201002337D0 (en) Compounds and their use
GB201018028D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use
GB201020848D0 (en) Compounds and their use